Search Results
You are looking at 1 - 1 of 1 items for
- Author: C. ROBISON x
- Refine by access: All content x
Search for other papers by V. C. JORDAN in
Google Scholar
PubMed
Search for other papers by S. KOERNER in
Google Scholar
PubMed
Search for other papers by C. ROBISON in
Google Scholar
PubMed
Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts 01545, U.S.A.
(Received 8 November 1974)
Oestrogens have been found to stimulate prolactin release in the rat (Chen & Meites, 1970) and increases in prolactin in the circulation have been reported to be essential for the maintenance and growth of dimethylbenz(α)anthracene (DMBA)-induced rat mammary carcinomata (Pearson, Molina, Butler, Llerena & Nasr, 1972). Non-steroidal anti-oestrogens retard the growth of DMBA-induced rat mammary carcinoma (Schulz, Haselmayer & Hölzel, 1971; Terenius, 1971) and one such compound nafoxidine (U-11, 100A) has been shown to inhibit oestrogen-stimulated prolactin release in rats (Heuson, Waelbroeck, Legros, Gallez, Robyn & L'Hermite, 1971–72) thereby suggesting a mechanism for antitumour activity which may occur simultaneously with tumour oestrogen receptor blockade (Terenius, 1971). The present investigation was undertaken to determine whether other anti-oestrogens could control oestrogen-stimulated prolactin release.
The non-steroidal anti-oestrogens ICI 46,474 (tamoxifen, trade name Nolvadex, trans 1-(ρ-β-dimethylaminoethoxyphenyl)-1,2-diphenyl but-1-ene) and MER 25 (ethamoxytriphetol,
